Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
FMS 
Fresenius Medical Care Corporation (FMS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/19/2025: FMS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $28.7
1 Year Target Price $28.7
| 1 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -12.8% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/19/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.63B USD | Price to earnings Ratio 16.44 | 1Y Target Price 28.7 |
Price to earnings Ratio 16.44 | 1Y Target Price 28.7 | ||
Volume (30-day avg) 6 | Beta 0.95 | 52 Weeks Range 21.46 - 29.71 | Updated Date 12/20/2025 |
52 Weeks Range 21.46 - 29.71 | Updated Date 12/20/2025 | ||
Dividends yield (FY) 3.47% | Basic EPS (TTM) 1.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3.66% | Operating Margin (TTM) 10.27% |
Management Effectiveness
Return on Assets (TTM) 3.33% | Return on Equity (TTM) 6.32% |
Valuation
Trailing PE 16.44 | Forward PE 9.42 | Enterprise Value 23778956152 | Price to Sales(TTM) 0.69 |
Enterprise Value 23778956152 | Price to Sales(TTM) 0.69 | ||
Enterprise Value to Revenue 1.03 | Enterprise Value to EBITDA 6.38 | Shares Outstanding 579697852 | Shares Floating 204526098 |
Shares Outstanding 579697852 | Shares Floating 204526098 | ||
Percent Insiders - | Percent Institutions 8.05 |
Upturn AI SWOT
Fresenius Medical Care Corporation
Company Overview
History and Background
Fresenius Medical Care AG & Co. KGaA was founded in 1996 through the merger of Fresenius AG's dialysis business and the acquisition of National Medical Care, Inc. It is a global leader in dialysis products and services. Significant milestones include its expansion into a global network of dialysis clinics and its development of innovative dialysis technologies. The company has evolved to offer a comprehensive range of renal care solutions.
Core Business Areas
- Dialysis Care and Services: Operates a vast network of dialysis clinics worldwide, providing life-sustaining hemodialysis and peritoneal dialysis treatments to patients with chronic kidney failure. This segment also includes a significant portion of its revenue from managing these clinics and offering related medical services.
- Renal Therapies and Technologies (Products): Develops, manufactures, and distributes a wide array of products essential for dialysis, including dialysis machines (dialyzers), hemodialysis concentrates, dialyzers, bloodlines, and other disposable medical devices. This segment also encompasses innovative products for home dialysis and chronic kidney disease management.
Leadership and Structure
Fresenius Medical Care AG & Co. KGaA is a publicly traded company with a dual-board system, common in German corporations. The Management Board is responsible for the operational management of the company, while the Supervisory Board oversees and advises the Management Board. Key leadership positions include the CEO and CFO.
Top Products and Market Share
Key Offerings
- Dialysis Clinics and Treatment Services: [object Object]
- Dialysis Machines and Consumables (e.g., Dialyzers, Concentrates): [object Object]
- Peritoneal Dialysis (PD) Solutions and Devices: [object Object]
Market Dynamics
Industry Overview
The global renal care market is driven by an increasing prevalence of chronic kidney disease (CKD), primarily due to rising rates of diabetes and hypertension, an aging population, and advancements in medical technology. The demand for dialysis treatments and related products is expected to continue growing steadily.
Positioning
Fresenius Medical Care is a global leader in the renal care industry, benefiting from its extensive network of dialysis clinics, diversified product portfolio, and strong brand recognition. Its integrated business model, encompassing both services and products, provides a competitive advantage. Key advantages include economies of scale, technological innovation, and established patient relationships.
Total Addressable Market (TAM)
The global dialysis market is substantial and growing, with estimates for the total addressable market for dialysis services and products ranging in the tens of billions of USD annually and projected to grow at a CAGR of 5-7% over the next decade. Fresenius Medical Care holds a significant share of this TAM through its extensive clinic network and product sales, making it a primary beneficiary of this growth.
Upturn SWOT Analysis
Strengths
- Extensive global network of dialysis clinics.
- Diversified revenue streams from both services and products.
- Strong brand reputation and long-standing customer relationships.
- Leadership in technological innovation in dialysis.
- Integrated business model from treatment to products.
Weaknesses
- High operational costs associated with running a large clinic network.
- Regulatory and reimbursement risks in various healthcare markets.
- Dependence on a specific patient population with chronic conditions.
- Potential for product recalls or manufacturing issues.
- Significant debt load from past acquisitions.
Opportunities
- Expansion into emerging markets with growing demand for renal care.
- Development and adoption of home dialysis technologies.
- Increased focus on value-based care models and integrated care pathways.
- Leveraging digital health and data analytics for improved patient outcomes.
- Strategic acquisitions to expand market reach or product offerings.
Threats
- Intensifying competition from established and emerging players.
- Changes in healthcare policies and reimbursement rates.
- Economic downturns impacting healthcare spending.
- Emergence of new treatment modalities that could disrupt the dialysis market.
- Geopolitical instability affecting global supply chains and operations.
Competitors and Market Share
Key Competitors
- DaVita Inc. (DVA)
- Baxter International Inc. (BAX)
- Nipro Corporation (JP:9742)
- B. Braun Melsungen AG (Privately Held)
Competitive Landscape
Fresenius Medical Care's competitive advantages lie in its scale, integrated model, and global reach. However, it faces intense competition from other large players like DaVita and Baxter, who also have significant market presence. The market is fragmented in some regions, with smaller, specialized providers also competing. Differentiation often comes through innovation in product technology, service quality, and cost-efficiency.
Major Acquisitions
National Medical Care, Inc.
- Year: 1996
- Acquisition Price (USD millions):
- Strategic Rationale: Formed Fresenius Medical Care as a global leader in dialysis services and products. This was a foundational acquisition.
Akebia Therapeutics Inc.
- Year: 2021
- Acquisition Price (USD millions): 100
- Strategic Rationale: Acquired the remaining stake in Akebia Therapeutics Inc. to strengthen its position in the pharmaceutical segment of renal care, focusing on anemia management in CKD patients.
Growth Trajectory and Initiatives
Historical Growth: Fresenius Medical Care has demonstrated consistent historical growth driven by organic expansion of its clinic network, strategic acquisitions, and increasing demand for its products and services in the face of rising CKD prevalence.
Future Projections: Analyst projections for future growth typically anticipate continued revenue expansion, driven by global demographic trends and an increasing number of CKD patients. Profitability improvement is a key focus for future growth, with ongoing efforts to optimize operational efficiency and manage costs.
Recent Initiatives: Recent initiatives include a comprehensive transformation program aimed at improving operational efficiency, strengthening the core business, and driving sustainable profitability. This involves optimizing its clinic network, enhancing its product portfolio, and investing in digital transformation and innovation.
Summary
Fresenius Medical Care is a global leader in renal care with a strong foundation in dialysis services and products. Its extensive clinic network and diversified offerings are key strengths, but profitability has been challenged by high operational costs and regulatory pressures. The company is undertaking a transformation program to improve efficiency and profitability, aiming to capitalize on the growing global demand for kidney disease management while navigating an increasingly competitive landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Fresenius Medical Care Official Investor Relations Website
- Annual Reports (10-K Filings)
- Quarterly Reports (10-Q Filings)
- Reputable Financial News Outlets (e.g., Bloomberg, Reuters)
- Market Research Reports (e.g., Statista, Grand View Research)
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Financial data provided is based on publicly available information and may not reflect the most up-to-date figures. Market share data is an approximation and can vary based on reporting methodologies. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fresenius Medical Care Corporation
Exchange NYSE | Headquaters - | ||
IPO Launch date 1996-09-19 | Chair of Management Board & CEO Ms. Helen Giza | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 109916 | |
Full time employees 109916 | |||
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, ambulant treatment, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.